omniture
思勤医疗SEEKIN

Latest News

SeekIn and OncoInv Collaborate to Expand the Global Accessibility of Multiple Cancer Detection Tests and Bridge Global Disparities in Cancer Care

SeekIn to Grant Oncolnv the Rights to Represent SeekIn's Comprehensive Range of Cancer Detection Te...

2023-12-15 21:00 1237

SeekIn Presents Retrospective and Prospective Validation Studies of SeekInCare Multi-omics Multi-cancer Early Detection test at the 20th ICGC Workshop and 7th ARGO Meeting in New York

One Retrospective Cohort, One Prospective Cohort, in Total of ~2,400 Cancer Patients and Non-cancer...

2023-11-10 21:00 1760

SeekIn Presents New Validation Studies of OncoSeek Multi-cancer Early Detection test at Early Detection of Cancer Conference in London

Two Sample Types, Three Different Platforms, Five Independent Cohorts of ~10,000 Cancer Patients an...

2023-10-16 20:00 1058

SeekIn paves the way for cancer early detection in low- and middle-income countries

OncoSeek® is a revolutionary multi-cancer early detection (MCED) test developed by SeekIn and empow...

2023-06-16 21:00 1992

SeekIn Receives CE-IVD Mark Approval for PanCanSeek® Cancer Mutation Detection Kit

First-of-its-kind one-for-all cancer mutation detection test SHENZHEN, China, Dec. 19, 2022 /PRNews...

2022-12-19 21:00 1413

SeekIn Receives CE-IVD Mark Approval for SeekInCure® Cancer Recurrence Monitoring Kit

First-of-its-kind blood-based pan-cancer recurrence monitoring test SHENZHEN, China, Nov. 28, 2022 ...

2022-11-28 21:00 3372

SeekIn Demonstrates the Power of Treatment Response Monitoring Test at the Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo

SeekInClarity is a CE-IVD Mark, cost-effective, blood-based pan-cancer/pan-indication treatment res...

2022-11-07 21:00 1355

SeekIn Presents New Data Supporting its Pan-cancer Early Detection Test at the Early Detection of Cancer Conference 2022

The large case-control study demonstrates that SeekInCare® has 68.0% sensitivity at 98.0% specifici...

2022-10-19 20:30 1103

SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test

This Blood-based Multi-Cancer Early Detection Test Combines Protein Tumor Markers And Artificial In...

2022-09-12 21:37 1193

SeekIn Receives CE Mark Approval for SeekInClarity™ Cancer Treatment Response Monitoring Kit

First-of-its-Kind blood-based pan-cancer treatment response monitoring test SHENZHEN, China, May 25...

2022-05-25 20:30 1755

SeekIn Receives CE Mark Approval for LeukoPrint® Molecular Karyotyping Test

First-of-its-Kind Molecular Karyotyping Test SHENZHEN, China, April 7, 2022 /PRNewswire/ -- SeekIn ...

2022-04-07 22:22 1594

SeekIn Receives CE Mark Approval for SeekInCare® Pan Cancer Early Detection Test

SHENZHEN, China, Feb. 24, 2022 /PRNewswire/ -- SeekIn Inc, the leader in blood-based cancer early d...

2022-02-24 21:34 1612